Tumor Markers and Colorectal Cancer: Utility in Management

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2004 Feb 6

PMID 14756436

Citations 13

Authors

Nigel P S Crawford

Daniel W Colliver

Susan Galandiuk

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Although genetic testing can screen for rare hereditary CRC syndromes, there is no ideal means of screening for sporadic forms of CRC. This review will focus on markers that are currently used in the management of sporadic CRC and their limitations, as well as possible future clinical applications.

Citing Articles

Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis.

Xun Z, Ding X, Zhang Y, Zhang B, Lai S, Zou D Nat Commun. 2023; 14(1):933.

PMID: 36806082 PMC: 9941488. DOI: 10.1038/s41467-023-36560-7.

Single Domain Antibodies as New Biomarker Detectors.

Leow C, Fischer K, Leow C, Cheng Q, Chuah C, McCarthy J Diagnostics (Basel). 2017; 7(4).

PMID: 29039819 PMC: 5745390. DOI: 10.3390/diagnostics7040052.

Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy.

Zhang L, OuYang P, Xiao W, Yu X, You K, Zeng Z Medicine (Baltimore). 2015; 94(45):e1793.

PMID: 26559251 PMC: 4912245. DOI: 10.1097/MD.0000000000001793.

Ectokinases as novel cancer markers and drug targets in cancer therapy.

Yalak G, Vogel V Cancer Med. 2014; 4(3):404-14.

PMID: 25504773 PMC: 4380966. DOI: 10.1002/cam4.368.

Association of CTTN polymorphisms with the risk of colorectal cancer.

Lee S, Kang D, Park W, Lee J, Cheon Chae S J Korean Surg Soc. 2012; 82(3):156-64.

PMID: 22403749 PMC: 3294109. DOI: 10.4174/jkss.2012.82.3.156.